Compare CTW & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTW | NGEN |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Japan | Canada |
| Employees | N/A | 9 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 197.5M |
| IPO Year | N/A | N/A |
| Metric | CTW | NGEN |
|---|---|---|
| Price | $2.48 | $1.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 17.5K | ★ 833.5K |
| Earning Date | 05-13-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.70 |
| 52 Week High | $3.14 | $5.93 |
| Indicator | CTW | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 37.30 |
| Support Level | $1.96 | $1.85 |
| Resistance Level | $3.05 | $2.28 |
| Average True Range (ATR) | 0.31 | 0.14 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 47.52 | 12.84 |
CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.